| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.003 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |